SCHEMBL17014346

SCHEMBL17014346

COc1ccc(C(C)=O)c2c1C1(CCCC1)CC2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
PDE4A P27815 2/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HTT P42858 1/20 0.35
ADRA1A P35348 1/20 0.34
NOTUM Q6P988 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17014327 0.81 ADRA1A (0.41) LMNAALDH1A1KDM4EGAAADRA1A
SCHEMBL17014335 0.81 ALDH1A1 (0.34) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL17014328 0.81 ALDH1A1 (0.41) ALDH1A1KDM4EGAAMAPTSMN1; SMN2
SCHEMBL17019626 0.80 HSD11B1 (0.36)
SCHEMBL17014455 0.78 ADRA1A (0.41) ALDH1A1KDM4EGAAPDE4AADRA1A
SCHEMBL17014347 0.76 LMNA (0.37) LMNAALDH1A1KDM4EGAACASP1
SCHEMBL18870484 0.74 MEN1 (0.34) LMNAALDH1A1PDE4AMEN1KMT2A
SCHEMBL15692819 0.74 LMNA (0.44) LMNAALDH1A1KDM4EHSD17B10GAA
SCHEMBL3427457 0.73 ALDH1A1 (0.50) LMNAALDH1A1KDM4EHSD17B10GAA
SCHEMBL12565602 0.73 ALDH1A1 (0.50) LMNAALDH1A1KDM4EHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900656-B1 SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS SUNSHINE LAKE PHARMA CO LTD (CN) 2017-05-17 EP disclosed
US-20150232509-A1 SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-08-20 US disclosed
US-20150232509-A1 SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS SUNSHINE LAKE PHARMA CO., LTD. (CN) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232509-A1 SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS HAVCR2, SLC10A1, SORD LMNA 2239/4885ALDH1A1 588/4885KDM4E 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.